Literature DB >> 8726031

Gastrointestinal tract colonization with vancomycin-resistant Enterococcus faecium in an animal model.

M S Whitman1, P G Pitsakis, E DeJesus, A J Osborne, M E Levison, C C Johnson.   

Abstract

Vancomycin-resistant enterococci have become important nosocomial pathogens in many institutions. The gastrointestinal tract of susceptible hosts serves as the likely reservoir from which the organism is disseminated. To study factors promoting colonization and the efficacy of decontamination therapy with antimicrobial agents, a model of gastrointestinal colonization with vancomycin-resistant Enterococcus faecium was developed in CF1 mice. At baseline, all animals were colonized with non-vancomycin-resistant enterococci (5.0 log10 CFU/g), but vancomycin-resistant organisms were not detectable. Following gastric inoculation with 5 x 10(8) CFU of a clinical isolate of vancomycin-resistant E. faecium, the strain transiently colonized the gastrointestinal tract of 100% of mice but was undetectable by Day 14 (< or = 2.7 log10 mean CFU/g). In animals who received 5 mg of streptomycin per ml or 250 micrograms of vancomycin per ml in drinking water, colonization with the organism occurred at significantly higher bacterial counts than in controls at 7 days following inoculation (9.4 for vancomycin, 9.2 for streptomycin, and 5.1 log10 mean CFU/g for controls; P < 0.05). Fecal concentrations of vancomycin-resistant E. faecium persisted at high counts through Day 22 in mice receiving these antibiotics, but low counts were also still detected in 3 of 10 control animals. In mice with previously established vancomycin-resistant E. faecium colonization, oral administration of ramoplanin, a lipoglycodepsipeptide to which the strain was susceptible, suppressed growth of all enterococci in feces, including the vancomycin-resistant strain after 7 days of therapy (< or = 3.1 and < or = 3.3 log10 mean CFU/g for vancomycin and streptomycin groups, respectively). All mice had a recurrence of colonization with vancomycin-resistant E. faecium after the ramoplanin was discontinued. In summary, this animal model demonstrates the importance of antibiotics in predisposing to gastrointestinal colonization with vancomycin-resistant Enterococcus spp. Although treatment with ramoplanin temporarily suppressed the organism, recurrence of colonization due to relapse or reinfection occurred.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726031      PMCID: PMC163361          DOI: 10.1128/AAC.40.6.1526

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

2.  Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study.

Authors:  M J Zervos; C A Kauffman; P M Therasse; A G Bergman; T S Mikesell; D R Schaberg
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

Review 3.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

4.  In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.

Authors:  A Bartoloni; M G Colao; A Orsi; R Dei; E Giganti; F Parenti
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

5.  Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward.

Authors:  E Rhinehart; N E Smith; C Wennersten; E Gorss; J Freeman; G M Eliopoulos; R C Moellering; D A Goldmann
Journal:  N Engl J Med       Date:  1990-12-27       Impact factor: 91.245

6.  In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial.

Authors:  M D O'Hare; G Ghosh; D Felmingham; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1990-02       Impact factor: 5.790

7.  Inhibition of peptidoglycan biosynthesis by ramoplanin.

Authors:  E A Somner; P E Reynolds
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 8.  Enterococcal bacteremia: clinical features, the risk of endocarditis, and management.

Authors:  D G Maki; W A Agger
Journal:  Medicine (Baltimore)       Date:  1988-07       Impact factor: 1.889

9.  In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.

Authors:  F Biavasco; E Manso; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

10.  Comparative in-vitro activity of vancomycin, teicoplanin, ramoplanin (formerly A16686), paldimycin, DuP 721 and DuP 105 against methicillin and gentamicin resistant Staphylococcus aureus.

Authors:  P A Maple; J M Hamilton-Miller; W Brumfitt
Journal:  J Antimicrob Chemother       Date:  1989-04       Impact factor: 5.790

View more
  10 in total

Review 1.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

2.  Increasing Antimicrobial Resistance: Therapeutic Implications for Enterococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

Review 3.  Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

4.  Clinical and epidemiological significance of enterococci intrinsically resistant to vancomycin (possessing the vanC genotype)

Authors:  B Toye; J Shymanski; M Bobrowska; W Woods; K Ramotar
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

Review 5.  Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications.

Authors:  L C McDonald; M J Kuehnert; F C Tenover; W R Jarvis
Journal:  Emerg Infect Dis       Date:  1997 Jul-Sep       Impact factor: 6.883

6.  A mouse model for characterization of gastrointestinal colonization rates among environmental Aeromonas isolates.

Authors:  Dennis J Lye
Journal:  Curr Microbiol       Date:  2009-01-09       Impact factor: 2.188

7.  Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice.

Authors:  Usha Stiefel; Nicole J Pultz; Marion S Helfand; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

8.  Intestinal translocation of clinical isolates of vancomycin-resistant Enterococcus faecalis and ESBL-producing Escherichia coli in a rat model of bacterial colonization and liver ischemia/reperfusion injury.

Authors:  Karin M van der Heijden; Inneke M van der Heijden; Flavio H Galvao; Camila G Lopes; Silvia F Costa; Edson Abdala; Luiz A D'Albuquerque; Anna S Levin
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

9.  Impact of single-room contact precautions on acquisition and transmission of vancomycin-resistant enterococci on haematological and oncological wards, multicentre cohort-study, Germany, January-December 2016.

Authors:  Lena M Biehl; Paul G Higgins; Jannik Stemler; Meyke Gilles; Silke Peter; Daniela Dörfel; Wichard Vogel; Winfried V Kern; Hanna Gölz; Hartmut Bertz; Holger Rohde; Eva-Maria Klupp; Philippe Schafhausen; Jon Salmanton-García; Melanie Stecher; Julia Wille; Blasius Liss; Kyriaki Xanthopoulou; Janine Zweigner; Harald Seifert; Maria J G T Vehreschild
Journal:  Euro Surveill       Date:  2022-01

10.  Intestinal colonization with Enterococcus faecium does not influence pulmonary defense against Pseudomonas aeruginosa in mice.

Authors:  Masja Leendertse; Rob J L Willems; Ida A J Giebelen; Joris J T H Roelofs; Janetta Top; Marc J M Bonten; Tom van der Poll
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.